As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.

All

    TOGGLE ALL / NONE

momenta logo blue green
Momenta Pharmaceuticals

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Stromedix
Stromedix

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

main-image-raze
Raze Therapeutics

Cancer therapeutics
targeting anabolic
tumor metabolism

main-image-numerate-FPO
Numerate

Small molecule
drug design
using statistical modeling

main-image-costim
CoStim Pharmaceuticals

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

crucell polio virus image
Crucell

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

micromet ALL-328-precursor-b-cell cropped
Micromet

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

decode chromosome image copy
deCODE genetics

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Bicycle
Bicycle Therapeutics

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

main-image-unum-FPO
Unum Therapeutics

Universal
cell-based
cancer immunotherapy

delinia-bio-t-cell-600x506
Delinia

Novel biologic
therapeutics for
autoimmune diseases

Harbor4b
Harbour Antibodies

Mouse platforms
for the generation of
fully human antibodies

main-image-infacare-FPO
Infacare

Proprietary pharmaceuticals
for neonatal care
and pediatrics

arqule c-met image for website
ArQule

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

main-image-ataxion-FPO
Ataxion

Therapies for rare,
debilitating, and underserved
neurological diseases

arrow hep c image for website
Arrow Therapeutics

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

main-image-vitae
Vitae Pharmaceuticals

Novel therapeutics using proprietary
computational chemistry –
IPO Sept 2014 (NASDAQ: VTAE)

Atlas600x506_forweb
AVROBIO

Cell and gene therapies
for rare diseases
and cancer

main-image-f-star
F-Star Alpha Limited

Bispecific antibodies
to improve the treatment
of serious diseases

Arteaus_portfolio
Arteaus Therapeutics

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Nimbus - gallery view
Nimbus Therapeutics

Breakthrough computer-aided
drug design
for transformative medicines

zafgen-full
Zafgen

First-in-class therapies for severe
obesity and rare genetic conditions –
IPO June 2014 (NASDAQ: ZFGN)

main-image-annovation
Annovation Biopharma

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Actelion PAH for website
Actelion

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Horizon2
Horizon Pharma

Specialty pharma focused on
chronic inflammatory diseases –
IPO July 2011 (NASDAQ: HZNP)

main-image-mnemosyne-FPO
Luc Therapeutics

Novel therapeutics for
schizophrenia and other
severe psychiatric diseases

main-image-surface
Surface Oncology

Cancer immunotherapies
at the interface of
innate & adaptive immunity

Spero---Fotolia_56849944_edit
Spero Therapeutics

Novel therapies
for severe, highly drug-resistant
bacterial infections

Eagalet-Mftng-image_edit
Egalet Corporation

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)

Print
Exelixis

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

main-image-synlogic
Synlogic

Next generation
synthetic biology platform
for novel therapeutics

ALNY-lab1 2 - cropped for web 2
Alnylam Pharmaceuticals

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

main-image-padlock
Padlock Therapeutics

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

main-image-navitor-FPO
Navitor Pharmaceuticals

Novel therapeutics
targeting
diseases of aging

Adnexus logo crop
Adnexus Therapeutics

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

main-image-rodin-FPO
Rodin Therapeutics

Behavioral epigenetic therapy
for cognitive
and neurodegenerative disease

main-image-avila
Avila Therapeutics

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

main-image-intellia-FPO
Intellia Therapeutics

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

obsidian-brand-image-final
Obsidian Therapeutics

New class of
regulated cell and
gene therapies

main-image-rana
RaNA Therapeutics

First-in-class
RNA therapies
for severe genetic diseases

hucal-platinum-072_1 2 - web crop
MorphoSys

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

main-image-quartet
Quartet Medicine

Biomarker-guided therapies
for chronic pain
and inflammation

U3 website header image 4 cropped for web
U3 Pharma

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

REPLIMUNE MAIN IMAGE-01
Replimune

Next-generation oncolytic
immunotherapies for
cancer treatment

main-image-miragen-FPO
miRagen Therapeutics

Innovative
micro-RNA-based
therapies

IMF-AtlasRectangle 600w
IFM Therapeutics

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

main-image-jenavalve
JenaValve

Minimally invasive
heart valve
devices

novexel BetaLactamaseComplex_1 for website
Novexel

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

main-image-lti-FPO
Lysosomal Therapeutics, Inc.

Discovering new medicines
for severe
neurodegenerative diseases